Skip to main content
Log in

Salicylate treatment in Kawasaki disease: high dose or low dose?

  • Immunology/Allergology
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Salicylate is the basic therapy for Kawasaki disease, however its optimal dose is controversial. We investigated the therapeutic efficacy of high dose (100 mg/kg per day,n=30) versus low dose (30 mg/kg per day,n=30) salicylate. Duration of fever, SGPT, serum salicylate, plasma thromboxane B2 (TxB2) and 6-ketoprostaglandin F1α (PGF1α) levels were compared before enrollment and on days 4,7 and 14 of treatment. In the high dose group, duration of fever was significantly shorter than that of the low dose group (3.2±0.3 versus 5.4±0.8 days,P<0.05), however, SGPT levels were significantly elevated (157±34 versus 48±11 IU/l,P<0.05). No differences in the incidence of coronary artery lesions were observed (5/30 versus 7/30). Plasma TxB2 production was completely blocked in both groups, and plasma 6-keto-PGF1α levels in the high dose group on day 14 was lower than that in the low dose group (39±8 versus 159±65 pg/ml,P<0.05). SGPT and plasma 6-keto-PGF1α correlated with serum salicylate concentration. These data suggest that high dose salicylate therapy may be disadvantageous as anti-thrombotic therapy, and supports the notion that low dose therapy is safe in the acute stage of Kawasaki disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

6-keto-PGF1α:

6-keto-prostaglandin F1α

TxB2 :

thromboxane B2

References

  1. Amano S, Hayama F, Tasaka K, Kubagawa H, Hamashima Y (1979) Pathology of Kawasaki disease. Pathology and morphogenesis of the vascular changes. Jpn Circ J 43:633–634

    PubMed  Google Scholar 

  2. Awakura M, Asai T (1986) The hepatic damage on Kawasaki disease and therapy. Prog Med (In Japanese) 6:162–168

    Google Scholar 

  3. Burch JW, Stanford N, Majerus PW (1978) Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61:314–319

    PubMed  Google Scholar 

  4. Burns JC, Glode MP, Clarke SH, Wiggins J, Hathaway WE (1984) Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients a high risk for development of coronary artery aneurysms. J Pediatr 105:206–211

    PubMed  Google Scholar 

  5. Fujiwara T, Fujiwara H, Ueda T, Nishioka K, Hamashima Y (1986) Comparison of macroscopic, ppstmortem, angiographic and two-dimensional echocardiographic findings of coronary aneurysms in children with Kawasaki disease. Am J Cardiol 57:761–764

    PubMed  Google Scholar 

  6. Fulton DR, Meissner HC, Peterson MB (1988) Effects of current therapy of Kawasaki disease on eicosanoid metabolism. Am J Cardiol 61:1323–1327

    PubMed  Google Scholar 

  7. Hamasaki Y, Ichimura T, Hattori T, Tasaki H, Miyazaki S (1986) Aspirin therapy for Kawasaki disease (MCLS): action for arachidonic acid metabolism in platelets and vascular endothelium. Acta Paediatr Jpn (In Japanese) 90:2214–2222

    Google Scholar 

  8. Hamasaki Y, Ichimura T, Tasaki H, Miyazaki S (1988) Studies on the effect of long-term use of low dose aspirin in Kawasaki disease. Acta Paediatr Jpn Overseas ed 30:63–67

    Google Scholar 

  9. Hanley SP, Bevan J, Cockbill SR, Heptinstall S (1981) Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet I: 969–971

    Google Scholar 

  10. Hicks RV, Melish ME (1986) Kawasaki syndrome. Pediatr Clin North Am 33:1151–1175

    PubMed  Google Scholar 

  11. Hidaka T, Nakano M, Ueta T, Komatsu Y, Yamamoto M (1983) Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease. J Pediatr 102:94–96

    PubMed  Google Scholar 

  12. Jacobs JC (1979) Salicylate treatment of epidemic Kawasaki disease in New York City. Ther Drug Monit 1:123–130

    PubMed  Google Scholar 

  13. Kato H, Koike S, Yokoyama T (1979) Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 63:175–179

    PubMed  Google Scholar 

  14. Kato H, Inoue O, Akagi T (1988) Kawasaki disease: cardiac problems and management. Pediatr Rev 9:209–217

    PubMed  Google Scholar 

  15. Koren G, MacLeod SM (1984) Difficulty in achieving therapeutic serum concentrations of salicylates in Kawasaki disease. J Pediatr 105:991–995

    PubMed  Google Scholar 

  16. Koren G, Rose V, Lavi S, Rowe R (1985) Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease. JAMA 254:767–769

    PubMed  Google Scholar 

  17. Koren G, Schaffer F, Silverman E, Walker S, Duffy C, Stein L, Suria D, Schue S, Thiessen JJ, Gelfand E, Laxer R (1988) Determination of low serum concentrations of salicylates in patients with Kawasaki disease. J Pediatr 112:663–667

    PubMed  Google Scholar 

  18. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341–347

    PubMed  Google Scholar 

  19. Research Committee on Kawasaki disease (1984) Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Ministry of Health and Welfare, Tokyo, Japan

    Google Scholar 

  20. Sasaguri Y, Kato H (1982) Regression of aneurysms in Kawasaki disease: a pathological study. J Pediatr 100:225–231

    PubMed  Google Scholar 

  21. Sasai K (1988) Plasma PGE2, TxB2, 6-keto PGF1α levels in patients with Kawasaki disease. Allergy (In Japanese) 37:952–958

    PubMed  Google Scholar 

  22. Sasai K, Furukawa S, Yabuta K (1987) The metabolism of the archidonic cascade in patients with Kawasaki disease. In: Shulman ST (ed) Kawasaki disease. Alan R. Liss, New York, pp 565–566

    Google Scholar 

  23. Takahashi M, Kato H (1987) Can consensus be reached in cardiac management of Kawasaki syndrome?: review of a survey among Japanese and U.S. pediatric cardiologists. In: Shulman ST (ed) Kawasaki disease. Alan R. Liss, New York, pp 493–508

    Google Scholar 

  24. The Kawasaki disease research committee (1986) A randomized controlled study of three different therapies for patients having Kawasaki disease. Act Paediatr Jpn (in Japanese) 90: 1844–1849

    Google Scholar 

  25. Yokoyama T, Kato H, Ichinose E (1980) Aspirin treatment and platelet function in Kawasaki disease. Kurume Med J 27:57–61

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akagi, T., Kato, H., Inoue, O. et al. Salicylate treatment in Kawasaki disease: high dose or low dose?. Eur J Pediatr 150, 642–646 (1991). https://doi.org/10.1007/BF02072625

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02072625

Key words

Navigation